Abstract WP231: The Incidence of Intracranial Hemorrhage in Patients Anticoagulated With Factor Xa Inhibitors (FXai): A Multi-Country Observational Study (AXIOM ICH)
Alexander T Cohen,Robert C Welsh,Jenneke Leentjens,Ali Canbay,Craig I Coleman,Satarupa Choudhuri,Chaozer Er,Chatree Chai-Adisaksopha,Douglas Dover,Liza Hoveling,Lisa Smits,Jil Billy Mamza,He Gao,Arsh Randhawa,Elena Babak,Wendy Beekman,Noortje Houthuizen,Felix Scherg,Katarina Kopke,Julia Winter,George Godfrey,Eddy Lang,Juan F Arenillas,On behalf of the AXIOM Rsch Group
DOI: https://doi.org/10.1161/str.55.suppl_1.wp231
IF: 10.17
2024-02-03
Stroke
Abstract:Stroke, Volume 55, Issue Suppl_1, Page AWP231-AWP231, February 1, 2024. Background:Intracranial haemorrhage (ICH) is associated with significant long-term morbidity, high healthcare costs and mortality. There is a paucity of accurate national incidence rate data on ICH, fatal ICH and ICH sub-types in patients on FXai anticoagulants (e.g. rivaroxaban and apixaban).Aim:To describe patient characteristics and incidence of ICH following the initial use of FXai in an ongoing multi-country study.Methods:A retrospective observational cohort analysis of electronic health records from new users of FXai in the UK and Canada. Individuals with FXai prescriptions for a therapeutic indication such as venous thromboembolism, atrial fibrillation (AF), and/or non-mechanical cardiac-valve replacement, were included. Demographic and clinical data were summarised using descriptive statistics, and incidence rates for ICH events were reported per 100 person-years with 95% confidence intervals. Subgroups have been analysed.Results:In the UK and Canada, there were a total of 383,433 new users of FXai; average age 69 years, 54% male, average BMI 29 kg/m2and 88% of patients used an oral FXai. The most common indication was AF (73%). 1650 and 438 ICH events were reported in the UK and Canada, with 1-year incidence rates of 0.56 and 0.72 per 100 person-years, 27% and 26% were fatal (Table), respectively. Event rates remain elevated in the years following FXai initiation.Conclusions:Findings indicate incidence rates of ICH in patients treated with FXai were consistent over time, approximately 0.64 per 100 person-years or 1:160 patients per year throughout the course of treatment. Case fatality rates are high, around 27%, remaining elevated in the years following FXai initiation.
peripheral vascular disease,clinical neurology